Emphasis will be two-fold in this report.
(1) Although the use of dicumarol is always accompanied by a calculated risk, under controlled conditions the response of prothrombin activity to dicumarol is reasonably predictable and orderly.
(2) The effectiveness of the anticoagulants has been reasonably established, but it must be emphasized that they are not infallible. The collected data representative of world-wide clinical experience have demonstrated the beneficial effects of heparin and dicumarol in reducing the morbidity and mortality associated with thrombo-embolism. These data are usually presented in statistical form and fail, therefore, to emphasize that in the face of intelligent use of the drugs, subsequent thrombo-embolism does sometimes occur. relief of pain and aching, fall in temperature and pulse curves, and subsidence of tenderness and swelling. In 16 cases, however, improvement was not evident until the concentrations was pushed below 20% and sometimes to less than 10%.
METHODS

Heparinization
In 7 cases actual progression of the thrombosis continued until these low levels were obtained. Symptomatic relief was obtained more quickly when heparin was used (2.8 days) than when dicumarol was employed alone (3.5 days). The thrombotic process, moreover, appeared to subside more quickly with the addition of heparin (6.8 days) than with dicumarol alone (7.5) .
Coincident with anticoagulant therapy satisfactory resolution of the thrombotic process was observed in 96% (128) A recent study (4) made in this institution indicates that the incidence of postoperative pulmonary embolism, over an eight year period, has been sharply reduced from 47 to 12 cases per year. In contrast, the incidence of pulmonary infarction in &dquo;cardiac&dquo; cases in this same period has remained essentially unchanged (9 to 11 cases per year). The Non fatal thrombo-embolism Four thrombo-embolic episodes were experienced despite anticoagulant therapy, by three patients (10%) who subsequently recovered.
One of these, a 60 year old woman, probably sustained a myocardial infarction 3 days before admission; the electrocardiographic signs were obscured by the presence of left bundle branch block. When first seen she was in shock and congestive failure, and pulmonary infarction had already occurred. Clinical evidence of peripheral venous thrombi was lacking. On the 5th hospital day dicumarol therapy was instituted. Satisfactory reduction of the prothrombin concentration prolonged over a period of 37 days did not prevent the recurrence of major pulmonary emboli. Recurrent congestive failure was a prominent feature of her illness. Her recovery, although prolonged over a course of 78 hospital days, was eventually satisfactory.
The second patient was a 48 year old male who had sustained a myocardial infarction for which he was treated at another hospital; anticoaglants were not employed. Twentyfour hours after the development of multiple arterial emboli to both lower extremities he was admitted to the University Hospital, 22 days after the initial infarction and about a week after its extension. The admission electrocardiogram indicated the presence of a recent and extensive anterolateral infarction which likely involved the interventricular septum. Ischemic gangrene of the left foot was present. At about 7:30 P.l~t. on the third hospital day, while straining on the bed pan, this patient sustained a cerebral embolism, despite the administration in the preceding 48 hours of 700 mgm. of heparin (the clotting time one hour after the accident was 2 minutes although previously it had varied from 7 to 22 minutes) and 600 mgm. of dicumarol. The prothrombin concentration 10 hours prior to the cerebral embolism was 50% and on the succeeding day it was 21%. Further thrombo-embolic complications did not occur; bilateral supracondylar amputations were, however, eventually required.
A third patient to whom dicumarol alone was administered for a posterior myocardial infarction of 4 days duration, had definite clinical evidence of extension of the infarction on the second day of anticoagulant therapy when the prothrombin concentration was 34%. The electrocardiogram at this time remained unchanged. Subsequently, while at effective prothrombin levels, she experienced continued episodes of chest pain, of several hours duration, accompanied by electrocardiographic evidence of extension of the infarction. On the 32d day of her convalescence, with sudden lapse of her prothrombin concentration from 19 to 37%, there was evidence of a minor but definite peripheral venous thrombosis, the symptoms and signs of which regressed with heparin and further dicumarolization.
In this group of patients, there was temporary &dquo;escape&dquo; of the prothrombin concentration above the therapeutic range on 32 different occasions. Coincident with the rise of prothrombin levels, peripheral vascular thrombosis or embolsim occurred in two. Three patients with such lapses eventually succumbed, but postmortem examination in 2 failed to prove that death would not have otherwise occurred.
The principal objectives to be attained by the use of anticoagulant therapy in myocardial infarctions include (5) the prevention of:
1. An extension of the coronary thrombosis or the occurrence of a second infarction, 2. The formation or extension of intraca.rdiac mural thrombi, 3. Peripheral and pelvis vein thromboses with secondary pulmonary embolism, 4 . Thromboses in peripheral and cerebral arteries. The recently reported cooperative study sponsored by the American Heart Association (2) substantiates the value of heparin and dicumarol in preventing these complications. In that study 432 patients received anticoagulants; 368, receiving only conventional therapy, constituted the &dquo;control group&dquo;. Twentyfour per cent of the control patients died as contrasted to a mortality of 15% in the treated patients. In 25% of the control series at least one or more thromboembolic complications developed, but in the patients treated with anticoagulants this incidence was only 11%. Although our series is much too small for comparison, it is of interest that the mortality rate (16%) and the incidence of thromboembolism (10%), among those patients who survived, are comparable.
If facilities are available, probably every patient with a myocardial infarction sustained not more than 3 weeks prior to hospitalization should be provided the protection of heparin and/or dicumarol. Although the gravity of subsequent thrombo-embolism may thereby certainly be lessened, the anticoagulant drugs are not complete insurance against these complications. In this small series, the incidence of thrombo-embolism prior to employment of heparin and/or dicumarol (16%) was not greatly different from that following treatment (10%). We have described the development, in spite of technically effective treatment, of peripheral arterial and venous thromboses, the occurrence of systemic and pulmonary emboli, and the extension of a myocardial infarction. Others (6, 7) The effect of dicumarol in reducing prothrombin is reasonably orderly, but absolute control cannot be anticipated since variation of prothrombin from the limits of the therapeutic range occurred in one-half of the cases in this series.
2. The increased incidence of thrombo-embolic episodes when the prothrombin concentration was above 30% is basis for our conviction that dicumarol must be used in sufficient quantities to secure and maintain concentrations below this figure.
3. Inasmuch as the hazard of bleeding is appreciable at low prothrombin levels, dicumarol cannot be administered safely without adequate daily laboratory control and hospitalization is advised for initiation of treatment. Under careful supervision, some patients may be continued on an out-patient basis but it should be recognized that the incidence of bleeding will be increased. 4. A low pretreatment prothrombin level is not in itself a reason for withholding dicumarol. To the recognized contraindications to anticoagulant therapy, we have added the patients with severe hypertension and past cerebro-vascular accidents. 5 . Large and frequently repeated doses of vitamin K are the antidote to an excessive effect of dicumarol on prothrombin. 6 . Although the anticoagulant drugs are unquestionably beneficial in reducing the frequency and gravity of thrombo-embolism, their protection is not always complete. Some cases of recurrent and fatal thrombo-embolism will be encountered in spite of technically effective ant.icoagulant therapy.
7. The high mortality rate among patients with organic heart disease and congestive failure from recurrent pulmonary infarctions on the basis of peripheral and/or intracardiac thrombi warrants more general use of the anticoagulant drugs in this group. Our study suggests that this treatment should be started much earlier than is currently practiced.
